Anna Roshal, MD
Hematology & Oncology · Saint Peters, MONPI 1124081799
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by AstraZeneca at 34.6% of the total. 2025 is the largest year on record at $7,282, more than ten times the $282 reported in 2019.
Across 44 payments — averaging $335.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- Avyxa Pharma, LLC$4K
- EMD Serono, Inc.$3K
- Jazz Pharmaceuticals Inc.$1K
- Deciphera Pharmaceuticals Inc.$500
- Daiichi Sankyo Inc.$360
- plus $797 from 15 others
Across 69 payments — averaging $2048.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$105K
- Merck$37K
What the payments were for
- Consulting fees$7,76053%
- Speaking & faculty fees$2,86019%
- Travel & lodging$3,35023%
- Food & beverage$7045%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $5,097 |
| Avyxa Pharma, LLC | 5 | $3,894 |
| EMD Serono, Inc. | 2 | $2,834 |
| Jazz Pharmaceuticals Inc. | 1 | $1,260 |
| Deciphera Pharmaceuticals Inc. | 1 | $500 |
| Daiichi Sankyo Inc. | 1 | $360 |
| Janssen Scientific Affairs, LLC | 1 | $350 |
| Genentech USA, Inc. | 5 | $93 |
| Amgen | 3 | $78 |
| Merck | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Tempus AI, Inc | 1 | $33 |
| Pharmacosmos Therapeutics Inc. | 1 | $25 |
| Array Biopharma Inc | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| Bristol Myers Squibb | 1 | $20 |
| Incyte Corporation | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Bayer | 1 | $11 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,743 in reported general payments places this provider in the 85th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 14 | $351,418 |
| OrserduElacestrant Hcl | 12 | $286,485 |
| TagrissoOsimertinib Mesylate | 16 | $260,702 |
| Abiraterone Acetate | 31 | $116,626 |
| EliquisApixaban | 35 | $26,469 |
| Ondansetron Hcl | 63 | $2,331 |
| Morphine Sulfate | 52 | $987 |
| Gabapentin | 90 | $886 |
| Potassium Chloride | 37 | $775 |
| Dexamethasone | 89 | $737 |
| Prochlorperazine Maleate | 67 | $663 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 38 | $566 |
| Olanzapine | 34 | $440 |
| Hydrocortisone | 16 | $403 |
| Morphine Sulfate ErMorphine Sulfate | 15 | $393 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $5,097 | $260,70216 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $350 | $116,62631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Saint Peters
- David SchlossmanColumbia$1.2M
- Mark FeslerSaint Louis$870K
- Kelly PendergrassLees Summit$189K
- Jonathan MizrahiSaint Louis$188K
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Muhammad MirzaWashington$65K
- Yifan TuSt. Louis$64K
- Whitney HensingKansas City$62K
- Shadi HaddadinJefferson City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.